Literature DB >> 15231239

Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease.

Rudy J Castellani1, Kazuhiro Honda, Xiongwei Zhu, Adam D Cash, Akihiko Nunomura, George Perry, Mark A Smith.   

Abstract

Metal-catalyzed hydroxyl radicals are potent mediators of cellular injury, affecting every category of macromolecule, and are central to the oxidative injury hypothesis of Alzheimer disease (AD) pathogenesis. Studies on redox-competent copper and iron indicate that redox activity in AD resides exclusively within the neuronal cytosol and that chelation with deferoxamine, DTPA, or, more recently, iodochlorhydroxyquin, removes this activity. We have also found that while proteins that accumulate in AD possess metal-binding sites, metal-associated cellular redox activity is primarily dependent on metals associated with nucleic acid, specifically cytoplasmic RNA. These findings indicate aberrations in iron homeostasis that, we suspect, arise primarily from heme, since heme oxygenase-1, an enzyme that catalyzes the conversion of heme to iron and biliverdin, is increased in AD, and mitochondria, since mitochondria turnover, mitochondrial DNA, and cytochrome C oxidative activity are all increased in AD. These findings, as well as studies demonstrating a reduction in microtubule density in AD neurons, suggest that mitochondrial dysfunction, acting in concert with cytoskeletal pathology, serves to increase redox-active heavy metals and initiates a cascade of abnormal events culminating in AD pathology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231239     DOI: 10.1016/j.arr.2004.01.002

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  20 in total

Review 1.  Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Tamar Amit
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

Review 2.  Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Biochem Pharmacol       Date:  2014-01-10       Impact factor: 5.858

Review 3.  Alzheimer disease.

Authors:  Rudy J Castellani; Raj K Rolston; Mark A Smith
Journal:  Dis Mon       Date:  2010-09       Impact factor: 3.800

4.  Capturing a reactive state of amyloid aggregates: NMR-based characterization of copper-bound Alzheimer disease amyloid β-fibrils in a redox cycle.

Authors:  Sudhakar Parthasarathy; Brian Yoo; Dan McElheny; William Tay; Yoshitaka Ishii
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

5.  A prochelator activated by hydrogen peroxide prevents metal-induced amyloid Beta aggregation.

Authors:  Marina G Dickens; Katherine J Franz
Journal:  Chembiochem       Date:  2010-01-04       Impact factor: 3.164

Review 6.  Oxidative stress and autophagy in the regulation of lysosome-dependent neuron death.

Authors:  Violetta N Pivtoraiko; Sara L Stone; Kevin A Roth; John J Shacka
Journal:  Antioxid Redox Signal       Date:  2009-03       Impact factor: 8.401

Review 7.  Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.

Authors:  Orly Weinreb; Tamar Amit; Orit Bar-Am; Moussa B H Youdim
Journal:  Br J Pharmacol       Date:  2015-12-01       Impact factor: 8.739

Review 8.  Phosphorylated tau: toxic, protective, or none of the above.

Authors:  Rudy J Castellani; Akihiko Nunomura; Hyoung-gon Lee; George Perry; Mark A Smith
Journal:  J Alzheimers Dis       Date:  2008-08       Impact factor: 4.472

9.  An N-heterocyclic amine chelate capable of antioxidant capacity and amyloid disaggregation.

Authors:  Kimberly M Lincoln; Timothy E Richardson; Lauren Rutter; Paulina Gonzalez; James W Simpkins; Kayla N Green
Journal:  ACS Chem Neurosci       Date:  2012-08-31       Impact factor: 4.418

10.  Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease.

Authors:  Bo Su; Haihua Liu; Xinglong Wang; Shu G Chen; Sandra L Siedlak; Eisaku Kondo; Raymond Choi; Atsushi Takeda; Rudy J Castellani; George Perry; Mark A Smith; Xiongwei Zhu; Hyoung-Gon Lee
Journal:  Mol Neurodegener       Date:  2009-07-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.